Aeterna Zentaris to Present Poster on Pharmacological and Toxicological Data on Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, at Upcoming ENDO Annual Meeting
Abstract #851112: "Pharmacological and Toxicological Evaluation of AEZS-130, a Novel, Oral Synthetic Growth Hormone Secretagogue//Ghrelin Receptor Agonist for the Diagnosis of Growth Hormone Deficiency", Babette Aicher, Peter Schmidt, Elena Bresciani, Vittorio Locatelli, Daniel Perrissoud, Michael Teifel Presenter: Dr. Babette Aicher, Associate Director - Screening & Profiling, Preclinical Development, Aeterna Zentaris Date and Time: Sunday, June 20, 2010, 1:30 pm - 3:30 pm (local time) Poster Board #: P2-340 Location: Halls D-G, San Diego Convention Center
A copy of this abstract is currently available on the ENDO website at www.endo-society.org.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.